USPlabs Crafts DMAA Defense As Shield Against Further Damage
This article was originally published in The Tan Sheet
Executive Summary
USPlabs’ compliance with FDA’s request to cease marketing DMAA-containing products came following lengthy and detailed responses to the agency that could shield the firm from class action lawsuits and state investigations.
You may also be interested in...
DoJ Prosecutions: USPlabs Guilty, DMBA Firm Indicted From FDA Investigations
USPlabs executives, others plead guilty to felony charges stemming from marketing unsafe products labeled as supplements but containing DMAA and linked to hepatitis. Blackstone Labs and other firms indicted on felony charges following FDA investigation for marketing DMBA-containing products. "It's all very welcome news, but I'm not sure this is going to change the overall environment," says Pieter Cohen, a physician who advocates for tighter regulation of supplement manufacturing and marketing.
Five Shanghai Suspects Charged After FDA Undercover Work On Spiked Supplements
One of the undeclared stimulant ingredients, 2-amino-6-methylheptane, or DMHA, is new on FDA's radar for violative ingredients used in products marketed as dietary supplements, while the other, 1,3-dimethylamylamine, DMAA, has long been a target of agency enforcement in the supplement sector.
Hi-Tech CEO Wheat Arrested In FDA Investigation Of Steroid-Spiked Supplements
Hi-Tech Pharmaceuticals CEO Jared Wheat and an associate face 18 criminal charges in federal court alleging they falsified FDA documents and distributed as supplements products containing steroid ingredient. Wheat is appealing the indictment to federal circuit court.